September 2, 2023

Ros­alind Brew­er is step­ping down from her post as Wal­greens CEO af­ter less than three years in the top job, the com­pa­ny said on Fri­day.

Roche’s alec­tinib, mar­ket­ed as Ale­cen­sa, helped cer­tain lung can­cer pa­tients stay dis­ease-free for longer fol­low­ing surgery in a Phase III study, the big phar­ma an­nounced

A can­cer care start­up found­ed by two Flat­iron Health alums in Au­gust raised $60 mil­lion to bring its val­ue-based ap­proach to can­cer care co­or­di­na­tion to

23andMe re­ceived FDA clear­ance to re­port an ad­di­tion­al 41 vari­ants in the BR­CA1 and BR­CA2 genes, which are as­so­ci­at­ed with a high­er risk of breast,

Am­gen has set­tled with the Fed­er­al Trade Com­mis­sion af­ter the US reg­u­la­tor in May had tried block­ing the Cal­i­for­nia drug­mak­er’s pro­posed near­ly $28 bil­lion ac­qui­si­tion

BioN­Tech is step­ping on As­traZeneca and Dai­ichi Sankyo’s turf with the launch of a Phase III tri­al for its an­ti­body-drug con­ju­gate aim­ing at a sub­set

Bavar­i­an Nordic is aban­don­ing its Covid-19 boost­er vac­cine af­ter Phase III re­sults — even though it did hit the pri­ma­ry end­point of the study —

Im­munother­a­py com­pa­ny Nex­Im­mune plans to lay off 22 of its 47 em­ploy­ees by Sep. 5 to re­duce the com­pa­ny’s ex­pens­es. John Train­er is va­cat­ing his

It’s a clas­sic bio­phar­ma sto­ry. In Jan­u­ary, David Khougaz­ian bumped in­to Flag­ship Pi­o­neer­ing founder Noubar Afeyan at the JP Mor­gan health­care con­fer­ence. They caught up,

Cancer patients experienced significantly higher rates of COVID-19-related deaths compared with the general public, according to two retrospective studies from the U.S. and Canada. In